Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
0 o) A+ F& B2 p3 ^; ^
I$ ]' \) B" `; y7 `6 A% `1 R
% e% R# e9 m7 I$ \! V; KSub-category:
- h' r; C. m$ _0 r$ {; aMolecular Targets 8 \7 C3 X- x, { e/ _% p% @
; T1 j; L+ }$ C" U4 O2 S# b) ^
) u/ u6 \- J' ]+ \4 l$ Y3 t) v
Category:7 j& F* H0 q* q7 r
Tumor Biology
- }; ?2 J1 B7 R+ }# G0 w' z% q# b. X" |% G. Q
' L' k. s0 a$ ZMeeting:4 S: l. H# {- y4 ?7 o. F( C, |* P
2011 ASCO Annual Meeting 4 u9 [! q/ ^) e% f1 L! V% M5 I
! G% G$ D4 X& n' V4 ~5 m+ j
$ M' ^/ ^( l6 q+ H3 z% A- N2 Y* jSession Type and Session Title:# Y, v+ X. j$ p
Poster Discussion Session, Tumor Biology
* Z, e$ E4 w3 b, [* G1 }
% U! Z& o; {8 n1 U: Y
& \2 y3 A3 P2 y$ G: D" p( i0 }Abstract No:, Q; D0 @' N3 W( `" l- e- V
10517
- y" E: _6 x6 u* c2 W
$ k T+ r6 v2 c% o( h
+ e1 F9 Q6 d$ yCitation:
$ m9 Z' y# S- t+ z o2 D L5 SJ Clin Oncol 29: 2011 (suppl; abstr 10517)
6 {, X L; H& t( D
5 y: [+ K0 N# k7 F3 d2 R& p( a5 @) U* I; V2 t: P) ]# k8 H
Author(s):
- `. @& P% c4 m" sJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
. P+ C( z9 L4 [# H- Q- {+ C3 j# ]- _% |" t4 e, u5 s6 y- i1 `
4 j# W/ F$ B0 O* X9 z# _ N; c- o3 C' g# j6 O1 M# l; Q$ f3 B( a
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 Z, p, W# r! q: h
/ y1 J( n- S& M0 x% J3 QAbstract Disclosures, B& y- Q3 q j( Y7 G/ d) s; j, ?
, K' T* C) ?6 l9 s# z( S
Abstract:
+ [% R* d p* D0 M) L9 ]6 W( y5 O* v+ Z C- S/ d/ W3 }7 O0 D
% j. s3 S' d' GBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.4 \6 c: {" a) Q4 H4 ^8 K
( l6 P8 g! n& E* z/ N 8 j1 I5 I+ `+ O) h% m
|
* \- d6 T% h1 c) J W x8 R7 H% F
显身卡
